Table 2.
Primary and secondary outcomes by neonate COVID-19 and MRI assessment status
| Outcomes | Neonates with COVID-19 (n = 8) | Neonates without COVID-19 (n = 64) | ||
|---|---|---|---|---|
| Received MRI (n = 5) | No MRI (n = 3) | Received MRI (n = 3) | No MRI (n = 61) | |
| White matter changes, n (%) | 3 (60) | NA | NA | NA |
| Physical growth at 44 wk CGA, n (%) | 5 (100) | 3 (100) | 3 (100) | 61 (100) |
| Weight (kg), median (IQR) | 4.6 (4.4–4.7) | 4.3 (4.3–4.5) | 4.3 (4.2–5.5) | 4.5 (4.3–5.0) |
| Length (cm), median (IQR) | 53 (53–55) | 53 (53–53) | 54 (52–56) | 54 (53–55) |
| Head circumference (cm), median (IQR) | 36 (36–36) | 35 (35–36) | 35 (35–38) | 36 (36–37) |
| Serological assessmentsa (anti-SARS-CoV-2 antibodies), n (%) | 3 (60) | 3 (100) | 1 (33) | 14 (23) |
| Maternal, n (%) | ||||
| IgG-positive before birth | 3 (100) | 3 (100) | 1 (100) | 14 (100) |
| IgM-positive before birth | 0 (0) | 2 (67) | 1 (100) | 4 (31) |
| Neonatal | ||||
| IgG-positive, n (%) | ||||
| At birth | NA | 2 (67) | NA | 3 (21) |
| 1 wk after birth | NA | 2 (67) | NA | NA |
| 2 wk after birth | 1 (33) | 2 (67) | 1 (100) | NA |
| 4 wk after birth | 1 (33) | 2 (67) | NA | NA |
| IgM-positive, n (%) | ||||
| At birth | 0 (0) | 1 (33) | 0 (0) | 0 (0) |
| 1 wk after birth | 0 (0) | 1 (33) | NA | NA |
| 2 wk after birth | 0 (0) | 1 (33) | NA | NA |
| 4 wk after birth | 1 (33) | 0 (0) | NA | NA |
MRI assessments at 44 weeks CGA. COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, NA not available, MRI magnetic resonance imaging, CGA correct gestational age, IQR interquartile range, Ig immunoglobulin. aanti-SARS-CoV-2 antibody expression was evaluated in 21 of the 72 maternal–neonatal pairs